6 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 1 | 1 | Terminated 1 |
Follow Glomerulonephritis, Membranous: new trials by email Literature Review of Glomerulonephritis, Membranous trials Research Report on Glomerulonephritis, Membranous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Peginterferon Alfa-2A 180 MCG/ML Injectable Solution - Membranous Nephropathy | Phase 2 | Terminated | Centre Hospitalier Universitaire de Nice | 4 | 2023-09-14 | 2026-06-18 |
| A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) efgartigimod IV, placebo - Membranous Nephropathy | Phase 2 | Terminated | argenx | 8 | 2023-02-20 | 2024-11-22 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) BCX9930 - Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | Phase 2 | Terminated | BioCryst Pharmaceuticals | 2 | 2022-02-18 | 2024-05-02 |
| Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy VB119 - Membranous Nephropathy | Phase 1 / Phase 2 | Terminated | Tenet Medicines | 6 | 2021-05-05 | 2026-02-12 |
| Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy LNP023, Rituximab - Idiopathic Membranous Nephropathy | Phase 2 | Terminated | Novartis Pharmaceuticals | 37 | 2019-11-23 | 2024-10-09 |
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 OMS721 (narsoplimab) - IgAN, LN | Phase 2 | Terminated | Omeros Corporation | 31 | 2016-03-10 | 2026-03-30 |
Glomerulonephritis, IGA (2) · Glomerulonephritis (1) · Glomerulonephritis, Membranoproliferative (1) · Kidney Diseases (1) · Lupus Nephritis (1) · Urologic Diseases (1)
Autoimmune Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Immune System Diseases (6) · Male Urogenital Diseases (6) · Nephritis (6) · Urogenital Diseases (6) · Glomerulonephritis (5) · Kidney Diseases (5) · Urologic Diseases (5) · Connective Tissue Diseases (1) · Lupus Erythematosus, Systemic (1) · Skin and Connective Tissue Diseases (1)
Interferon-alpha (1) · Rituximab (1) · narsoplimab (1) · peginterferon alfa-2a (1)
BioCryst Pharmaceuticals (1) · Centre Hospitalier Universitaire de Nice (1) · Novartis Pharmaceuticals (1) · Omeros Corporation (1) · Tenet Medicines (1) · argenx (1)
China (2) · France (2) · Spain (2) · United Kingdom (2) · United States (2) · Argentina (1) · Czechia (1) · Germany (1) · Hong Kong (1) · India (1) · Italy (1) · Netherlands (1) · Taiwan (1)
Carla M Nester, MD, MSA, FASN (1)
2019 (1)